S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
New CBOE “special perk” helps traders target income every weekend (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts

Axonics (AXNX) Stock Forecast & Price Target

$57.50
+1.51 (+2.70%)
(As of 12/1/2023 ET)
Compare
Today's Range
$55.61
$58.06
50-Day Range
$49.38
$59.14
52-Week Range
$47.59
$71.68
Volume
642,828 shs
Average Volume
439,949 shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.60

Axonics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$71.60
24.52% Upside
High Forecast$75.00
Average Forecast$71.60
Low Forecast$63.00
TypeCurrent Forecast
12/3/22 to 12/3/23
1 Month Ago
11/3/22 to 11/3/23
3 Months Ago
9/4/22 to 9/4/23
1 Year Ago
12/3/21 to 12/3/22
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$71.60$71.60$76.36$80.78
Predicted Upside24.52% Upside37.12% Upside27.71% Upside18.81% Upside
Get Axonics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.


AXNX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AXNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Axonics Stock vs. The Competition

TypeAxonicsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside24.52% Upside646.65% Upside2,853.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$84.00 ➝ $75.00+48.02%
10/31/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$76.00 ➝ $69.00+39.39%
10/31/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$76.00 ➝ $63.00+27.27%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
10/16/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$70.00+27.78%
7/28/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$69.00 ➝ $70.00+32.08%
7/28/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$70.00 ➝ $71.00+33.96%
7/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$75.00+43.35%
7/12/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$85.00 ➝ $75.00+49.58%
5/23/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$75.00+45.32%
4/17/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$82.00 ➝ $73.00+26.67%
(Data available from 12/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AXNX Price Target - Frequently Asked Questions

What is Axonics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Axonics stock is Buy based on the current 10 buy ratings for AXNX. The average twelve-month price prediction for Axonics is $71.60 with a high price target of $75.00 and a low price target of $63.00. Learn more on AXNX's analyst rating history.

Do Wall Street analysts like Axonics more than its competitors?

Analysts like Axonics more than other Medical companies. The consensus rating for Axonics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how AXNX compares to other companies.

Does Axonics's stock price have much upside?

According to analysts, Axonics's stock has a predicted upside of 37.12% based on their 12-month stock forecasts.

What analysts cover Axonics?

Axonics has been rated by Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AXNX) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -